Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 10/20 | 0.52 |
| ▸ | ESR2 | Q92731 | 9/20 | 0.52 |
| ▸ | ENPP3 | O14638 | 6/20 | 0.46 |
| ▸ | ENPP1 | P22413 | 6/20 | 0.46 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.44 |
| ▸ | STS | P08842 | 1/20 | 0.43 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | PLD2 | O14939 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | C5 | P01031 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | FYN | P06241 | 1/20 | 0.42 |
| ▸ | PGR | P06401 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7944330 | 0.98 | ESR1 (0.51) | ESR1ESR2ENPP3ENPP1ABCC1 | |
| SCHEMBL7944288 | 0.98 | ESR1 (0.51) | ESR1ESR2ENPP3ENPP1ABCC1 | |
| SCHEMBL7942816 | 0.97 | ESR1 (0.50) | ESR1ESR2ENPP3ENPP1ABCC1 | |
| SCHEMBL8978096 | 0.83 | ESR1 (0.51) | ESR1ESR2ENPP3ENPP1ABCC1 | |
| SCHEMBL7092816 | 0.82 | ESR1 (0.63) | ESR1ESR2ENPP3ENPP1ITGA4 | |
| Hydrochloric Acid SCHEMBL8866853 | 0.82 | ENPP3 (0.56) | ESR1ESR2ENPP3ENPP1ABCC1 | |
| SCHEMBL987943 | 0.81 | ESR1 (0.64) | ESR1ESR2MEN1PLD2KDM1A | |
| SCHEMBL4651812 | 0.81 | ESR1 (0.71) | ESR1ESR2ENPP3ENPP1ABCC1 | |
| Hydrochloric Acid SCHEMBL3974968 | 0.80 | ESR1 (0.64) | ESR1ESR2MEN1PLD2KDM1A | |
| SCHEMBL4651711 | 0.80 | ESR1 (0.69) | ESR1ESR2ENPP3ENPP1ABCC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5482949-A | INHIBITING BONE LOSS, LOWERING CHOLESTEROL LEVELS, AND TREATING ESTROGEN DEPENDENT MAMMARY OR UTERINE CARCINOMA | ELI LILLY AND COMPANY (US) | 1996-01-09 | — | — | US | claimed |
| EP-0617030-A1 | Sulfonate and carbamate derivatives of 3-aroylbenzo (beta) thiophenes | ELI LILLY AND COMPANY (US) | 1994-09-28 | — | — | EP | claimed |
| US-6221838-B1 | Methods of treating neuropeptide Y-associated conditions | ELI LILLY AND COMPANY | 2001-04-24 | — | — | US | disclosed |
| US-6121292-A | BY ADMINSTERING A SUBSTITUTED BENZOFURAN, BENZOTHIOPHENE, INDOLE, OR (DIHYDRO)NAPHTHYLENE, OF GIVEN FORMULA SUCH AS (6-(N-BUTYLSULFONOYL)-2-(4(N-BUTYLSULFONYL)PHENYL)BENZO(B)-THIEN-3-YL)(4(2 -(1-PIPERIDINYL)ETHOXY)PHENYL)METHANONE | ELI LILLY AND COMPANY (US) | 2000-09-19 | — | — | US | disclosed |
| US-5972888-A | LOWERING THE PRODUCTION OR RELEASE OF NEUROPEPTIDE Y WHICH COMPRISES ADMINISTERING TO A MAMMAL IN NEED THEREOF AN EFFECTIVE AMOUNT OF AN ISOLATED NATURALLY OCCURRING OBESITY PROTEIN, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ELI LILLY AND COMPANY (US) | 1999-10-26 | — | — | US | disclosed |
| EP-0617030-B1 | Sulfonate and carbamate derivatives of 3-aroylbenzo (beta) thiophenes | LILLY CO ELI (US) | 1999-05-26 | — | — | EP | disclosed |
| EP-0895781-A2 | Use of benzofurans, benzothiophenes or indoles for the manufacture of a medicament for the treatment of conditions associated with an excess of tachykinins | ELI LILLY AND COMPANY (US) | 1999-02-10 | — | — | EP | disclosed |
| EP-0820769-A2 | Use of benzothiophenes for the manufacture of a medicament for the treatment of diseases associated with an excess of tachykinis | ELI LILLY AND COMPANY (US) | 1998-01-28 | — | — | EP | disclosed |
| EP-0759441-A2 | Methods of treating neuropeptide Y-associated conditions | ELI LILLY AND COMPANY (US) | 1997-02-26 | — | — | EP | disclosed |
| US-5605924-A | USEFUL IN PREVENTING BONE LOSS, TREATING HYPERCHOLESTEREMIA AND TREATING HORMONE DEPENDENT MAMMALIAN BREAST AND UTERINE CARCINOMA | ELI LILLY AND COMPANY (US) | 1997-02-25 | — | — | US | disclosed |
| EP-0754464-A2 | Methods of treating neuropeptide Y-associated conditions | ELI LILLY AND COMPANY (US) | 1997-01-22 | — | — | EP | disclosed |
| EP-0716854-A2 | Compositions for inhibiting neuropeptide y receptors | ELI LILLY AND COMPANY (US) | 1996-06-19 | — | — | EP | disclosed |
| WO-1996012488-A1 | BICYCLIC BRADYKININ RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1996-05-02 | — | — | WO | disclosed |
| EP-0709090-A2 | Compositions for treating resistant tumors | ELI LILLY AND COMPANY (US) | 1996-05-01 | — | — | EP | disclosed |
| WO-1996011677-A1 | METHODS FOR TREATING RESISTANT TUMORS | ELI LILLY AND COMPANY (US) | 1996-04-25 | — | — | WO | disclosed |
| EP-0707852-A2 | Bicyclic bradykinin receptor antagonists | ELI LILLY AND COMPANY (US) | 1996-04-24 | — | — | EP | disclosed |
| US-5482949-A | INHIBITING BONE LOSS, LOWERING CHOLESTEROL LEVELS, AND TREATING ESTROGEN DEPENDENT MAMMARY OR UTERINE CARCINOMA | ELI LILLY AND COMPANY (US) | 1996-01-09 | — | — | US | disclosed |
| EP-0617030-A1 | Sulfonate and carbamate derivatives of 3-aroylbenzo (beta) thiophenes | ELI LILLY AND COMPANY (US) | 1994-09-28 | — | — | EP | disclosed |